Imprinted H19 oncofetal RNA is a candidate tumour marker for hepatocellular carcinoma

Journal of Clinical Pathology - Molecular Pathology

Volumn 51, Issue 1, 1998, Pages 21-25

  Ariel, I ^a   Miao, H Q ^a   Ji, X R ^c   Schneider, T ^b   Roll, D ^a   De Groot, N ^b   Hochberg, A ^b   Ayesh, S ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c QINGDAO UNIVERSITY   (China)

Author keywords

H19; Hepatocellular carcinoma; fetoprotein

Indexed keywords

ALPHA FETOPROTEIN; RNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CYTODIAGNOSIS; CLINICAL ARTICLE; CYTOGENETICS; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL;

EID: 0031943145     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.51.1.21     Document Type: Article

References (44)

1. Feinberg AP. Genomic imprinting and gene activation in cancer. Nat Genet 1993;4:110-13.
2. Hochberg A, Gonik B, Goshen R, et al. A growing relationship between genomic imprinting and tumorigenesis. Cancer Genet Cytogenet 1994;73:82-3.
3. Tycko B. Genomic imprinting: mechanism and role in human pathology. Am J Pathol 1994;144:431-43.
4. De Souza AT, Yamada T, Mills JJ, et al. Imprinted genes in liver carcinogenesis. FASEB J 1997;11:60-7.
5. Rachmilewitz J, Goshen R, Ariel I, et al. Parental imprinting of the human H19 gene. FEBS Lett 1992;309:25-8.
6. Zhang Y, Tycko B. Monoallelic expression of the human H19 gene. Nat Genet 1992;1:40-4.
7. Hao Y, Crenshaw M, Moulton T, et al. Tumour-suppressor activity of H19 RNA. Nature 1993;365:764-7.
8. Ariel I, Lustig O, Oyer CE, et al. Relaxation of imprinting in trophoblastic disease. Gynecol Oncol 1994;53:212-19.
9. Ariel I, Lustig O, Schneider T, et al. The imprinted H19 as a tumor marker in bladder carcinoma. Urology 1995;45:335-8.
10. Ariel I, Ayesh S, Perlman EJ, et al. The product of the imprinted H19 gene is an oncofetal RNA. J Clin Pathol: Mol Pathol 1997;50:34-44.
11. Biran H, Ariel I, de Groot N, et al. Human imprinted genes as oncodevelopmental markers. Tumor Biol 1994;15:123-34.
12. Goshen R, Rachmilewitz J, Schneider T, et al. The expression of the human H19 and IGF2 genes during human embryogenesis and placental development. Mol Reprod Dev 1993;34:374-9.
13. Lustig O, Ariel I, Ilan J, et al. Expression of the imprinted H19 gene in the human fetus. Mol Reprod Dev 1994;38: 239-46.
14. Pachnis V, Belagew A, Tilghman SM. Locus unlinked to α-fetoprotein under the control of the murine raf and Rif genes. Proc Natl Acad Sci USA 1984;84:5523-7.
15. Li X, Nong Z, Ekstrom C, et al. Disrupted IGF2 promoter control by silencing of promoter P1 in human hepatocellular carcinoma. Cancer Res 1997;57:2048-54.
16. Brannan CI, Dees EC, Ingram RS, et al. The product of the H19 gene may function as an RNA. Mol Cell Biol 1990;10: 28-36.
17. Brockdorf N, Ashworth A, Kay GF, et al. The product of the mouse Xist gene is a 15 kb inactive X specific transcript containing no conserved ORF and located in the nucleus. Cell 1992;71:515-26.
18. Wevrick R, Kerns JA, Francke U. Identification of a novel paternally expressed gene in the Prader-Willi syndrome region. Hum Mol Genet 1994;3:1877-82.
19. Rastinejad F, Conboy MJ, Rando TA, et al. Tumor suppression by RNA from the 3′ untranslated region of α-tropomyosin. Cell 1993;75:1107-17.
20. Abelev GI. Alpha-fetoprotein: 25 years of study. Tumor Biol 1989;10:63-74.
21. Tatarinov YS. The past and the future for cancer testing by alpha-fetoprotein. A review. J Nucl Med Allied Sci 1989;33(suppl 3):5-11.
22. Zvibel I, Brill S, Reid LM. Insulin-like growth factor II regulation of gene expression in rat and human hepatomas. J Cell Physiol 1995;162:36-43.
23. Voutilainen R, Ilvesmaki V, Ariel I, et al. Parallel regulation of parentally imprinted H19 and insulin-like growth factor-II genes in cultured human fetal adrenal cells. Endocrinology 1994;134:2051-6.
24. Ariel I, Weinstein D, Voutilainen R, et al. Genomic imprinting and the endometrial cycle. the expression of the imprinted gene H19 in the human female reproductive organs. Diagn Mol Pathol 1997;6:17-25.
25. Eversole-Cire P, Fergusson-Smith AC, Surani AM, et al. Coordinate regulation of Igf-2 and H19 in cultured cells. Cell Growth Diff 1995;6:337-45.
26. Elkin M, Shevelev A, Schulze E, et al. The expression of the imprinted H19 and IGF-2 genes in human bladder carcinoma. FEBS Lett 1995;374:57-61.
27. Kondo M, Suzuki H, Ueda R, et al. Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers. Oncogene 1995;10: 1193-8.
28. Taniguchi T, Sullivan MJ, Ogawa O, et al. Epigenetic changes encompassing the IGF2/H19 locus associated with relaxation of IGF2 imprinting and silencing of H19 in Wilms' tumor. Proc Natl Acad Sci USA 1994;92:2159-63.
29. Van Gurp RJLM, Oosterhuis JW, Kalscheuer V, et al. Human testicular germ cell tumors show biallelic expression of the H19 and IGF2 gene. J Natl Cancer Inst 1994;86: 1070-5.
30. Yballe CM, Vu TH, Hoffman AR. Imprinting and expression of insulin-like growth factor-II and H19 in normal breast tissue and breast tumor. J Clin Endocrinol Metab 1996;81:1607-12.
31. Leighton PA, Ingram RS, Eggenschwiler J, et al. Disruption of imprinting caused by deletion of the H19 region in mice. Nature 1995;375:34-9.
32. Cariani E, Lassere C, Kemeny F, et al. Differential expression of insulin-like growth factor II mRNA in human primary liver cancer, benign liver tumors and liver cirrhosis. Cancer Res 1988;48:6844-9.
33. d'Arville CN, Nouri-Aria KT, Johnson P, et al. Regulation of insulin-like growth factor II gene expression by hepatitis B virus in hepatocellular carcinoma. Hepatology 1991;13: 310-15.
34. Fiorentino M, Grigioni WF, Baccarini P, et al. Different in situ expression of insulin-like growth factor type II in hepatocellular carcinoma. An in situ hybridization and immunohistochemical study. Diagn Mol Pathol 1994;3:59-65.
35. Su Q, Liu YF, Zhang JF, et al. Expression of insulin-like growth factor II in hepatitis B, cirrhosis and hepatocellular carcinoma: its relationship with hepatitis B antigen expression. Hepatology 1994;20:788-99.
36. Ueda K, Ganem D. Apoptosis is induced by N-myc expression in hepatocytes, a frequent event in hepadnavirus oncogenesis, and is blocked by insulin-like growth factor II. J Virol 1996;70:1375-83.
37. Yang D, Faris R, Hixon D, et al. Insulin-like growth factor II blocks apoptosis of N-myc2-expressing woodchuck liver epithelial cells. J Virol 1996;70:6260-8.
38. Tabor E. Tumor suppressor genes, growth factor genes, and oncogenes in hepatitis B virus-associated hepatocellular carcinoma. J Med Virol 1994;42:357-65.
39. Casola S, Ungaro P, Padone PV, et al. Loss of heterozygosity of imprinted genes in SV/40 t/T antigen induced hepatocellular carcinoma. Oncogene 1995;11:711-21.
40. Rogler CE, Sherman M, Su CY, et al. Deletion in chromosome 11p associated with a hepatitis B integration site in hepatocellular carcinoma. Science 1985;230:319-22.
41. Christiansen M, Ishiguro T, Hogdall C, et al. Alpha-fetoprotein. In: Ballesta AM, et al, eds. Updating on tumor markers in tissues and biological fluids. Torino: Edizioni Minerva Medica, 1993:245-69.
42. Hurlimann J, Gardiol D. Immunohistochemistry in the differential diagnosis of liver carcinomas. Am J Surg Pathol 1991;15:280-8.
43. Guindi M, Yazdi HM, Gilliatt MA. Fine needle aspiration biopsy of hepatocellular carcinoma. Value of immunohistochemical and ultrastructural studies. Acta Cytol 1994;38: 385-91.
44. Wee A, Nilsson B, Tan LK, et al. Fine needle aspiration biopsy of hepatocellular carcinoma. Diagnostic dilemma at the ends of the spectrum. Acta Cytol 1994;38:347-54.